Zepbound Approved for Sleep Apnea

Health Canada just approved Zepbound, a groundbreaking GLP-1 drug from Eli Lilly, as the first of its kind in Canada to treat severe obstructive sleep apnea in obese adults. This new injection, containing tirzepatide, targets appetite hormones to drive weight loss — a key factor in managing sleep apnea — and showed dramatic results in clinical trials: up to 29 fewer breathing interruptions per hour for CPAP users and 25 for non-users. While it’s not a replacement for CPAP machines, it offers a powerful new tool for those struggling with this often-overlooked condition that can lead to heart attacks, strokes, and chronic fatigue. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3c5bc534024e7761